Dear shareholders and shareholder representatives:
In 2025, I served as the independent director of Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "the Company"). During my tenure, I strictly adhered to the provisions of the Company Law, Securities Law, Management Measures for Independent Directors of Listed Companies, and the Shenzhen Stock Exchange Self-Regulatory Guidelines No. 2 for the standardized operation of GEM listed companies, as well as the Company's Articles of Association. I diligently fulfilled my duties, exercised the supervisory role of an independent director, and safeguarded the overall interests of the Company and the legitimate rights and interests of all shareholders, especially minority shareholders. Below is my performance report for 2025:
I. Basic Information of the Independent Director
Born in 1959, I am a Chinese national without permanent residency abroad, holding a doctoral degree and serving as a professor who enjoys special government allowances from the State Council. I have long been engaged in teaching and research in medical biology. Since 2006, I have been a professor and doctoral supervisor at the School of Life Sciences, Xiamen University, and a specially appointed professor of the "Minjiang Scholar" program in Fujian Province. I have served as the independent director of the Company since August 14, 2024. My position meets the independence requirements stipulated in Article 6 of the Management Measures for Independent Directors of Listed Companies, and there are no circumstances affecting my independence.
II. Overview of Independent Director's Annual Performance
(1) Attendance at Board Meetings and Shareholder Meetings
In 2025, the Company held 7 board meetings, 1 annual general meeting, and 2 extraordinary general meetings. I attended all meetings on time and did not delegate my attendance to other independent directors. I believe that the convening and holding of the board meetings were legal and compliant, and that necessary approval procedures were followed for significant matters. The relevant proposals were in the interest of all shareholders and did not harm the legitimate rights and interests of the Company and minority shareholders. I exercised my voting rights prudently, voting in favor of all board proposals and other matters without raising objections or abstaining. During the reporting period, I did not propose to convene a board meeting.